Novel stromelysin inhibitors
OwnerCordula Hopmann, Martin Albert Knauf +2inventors
InventorsCordula Hopmann, Martin Albert Knauf, Klaus-Ulrich Weithmann, Joachim Wink
Life of this patent
Estimating the term…
Abstract
Compounds of the formula I 1 are suitable for the production of pharmaceuticals for the prophylaxis and therapy of conditions whose course involves an increased activity of matrix-degrading enzymes, in particular stromelysin.
Claims24
A compound of the formula I 4
- wherein R1 is selected from
- a (C3-C10) linear or branched aklyl group which is unsubstituted, monosubstituted, disubstituted, or trisubstituted with a group selected from
- —OR3 where R3 is selected from hydrogen and a (C1-C4)-alkyl;
- NR4R5 where R4 and R5 are independently selected from hydrogen and a (C1-C4)-alkyl;
- a halogen;
- ═O;
- and
- —COOH;;
- and
- a (C3-C10) linear or branched alkenyl group which is unsubstituted, monosubstituted, disubstituted, or trisubstituted with a group selected from
- —OR3 where R3 is selected from hydrogen and a (C1-C4)-alkyl;
- NR4R5 where R4 and R5 are independently selected from hydrogen and a (C1-C4)-alkyl;
- a halogen;
- ═O;
- and
- —COOH;;
- R2 is selected from
- a (C3-C10) linear or branched aklyl group which is unsubstituted, monosubstituted, disubstituted, or trisubstituted with a group selected from
- —OR3 where R3 is selected from hydrogen and a (C1-C4)-alkyl;
- NR4R5, where R4 and R5 are independently selected from hydrogen and a (C1-C4)-alkyl;
- a halogen;
- ═O;
- and
- —COOH;
- and
- a (C3-C10) linear or branched alkenyl group which is unsubstituted or monosubstituted, disubstituted, or trisubstituted with a group selected from
- —OR3 where R3 is selected from hydrogen and a (C1-C4)-alkyl;
- NR4R5, where R4 and R5 are independently selected from hydrogen and a (C1-C4)-alkyl;
- a halogen;
- ═O;
- and
- —COOH;
- and
- Z is a hexose which is in pyranoid form via a C-glycosidic bond, or a stereoiosmer or physiologically tolerable salt thereof.
The compound stromemycin having the following structure 5
A method of treatment or prophylaxis of conditions involving increased activity of matrix-degrading metalloproteinases comprising administering a pharmaceutically effective amount of a compound of formula I to an animal or human host in need thereof.
A method of treatment or prophylaxis of conditions involving increased activity of matrix-degrading metalloproteinases comprising administering a pharmaceutically effective amount of stromemycin to an animal or human host in need thereof.
A method for treating tissue disorders selected from osteoarthrosis, spondylosis, chondrolysis after joint trauma or relatively long joint immobilization after meniscus or patella injuries or tearing of the ligaments, collagenoses, periodontal conditions, wound healing disorders, chronic conditions of the locomotory apparatus, inflammatorily, immunologically or metabolically caused acute and chronic arthritis, arthropathy, myalgia, disorders of the bone metabolism, ulceration, atherosclerosis, stenoses, inflammation, carcinomatous disorders, formation of tumor metasases, cachexia, anorexia, and septic shock comprising administering a pharmaceutically acceptable amount of a compound of formula I to an animal or human host in need thereof.
A method for treating tissue disorders selected from osteoarthrosis, spondylosis, chondrolysis after joint trauma or relatively long joint immobilization after meniscus or patella injuries or tearing of the ligaments, collagenoses, periodontal conditions, wound healing disorders, chronic conditions of the locomotory apparatus, inflammatorily, immunologically or metabolically caused acute and chronic arthritis, arthropathy, myalgia, disorders of the bone metabolism, ulceration, atherosclerosis, stenoses, inflammation, carcinomatous disorders, formation of tumor metasases, cachexia, anorexia, and septic shock comprising administering a pharmaceutically acceptable amount of stromemycin to an animal or human host in need thereof.
Dependencies are inferred from the claim text.